Editorial: Reactive oxygen species signaling: opportunities and challenges in cancer therapy
Frontiers in Physiology · 03.11.2026 · 17
DOI: 10.3389/fphys.2026.2025961 ↗Kurz gefasst
Editorial in der Zeitschrift Frontiers in Physiology, online erschienen am 03.11.2026. Verfasst von Seema Kumari und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Dr. B. R. Ambedkar University, Srikakulam, Andhra Pradesh, India. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The review by Kumari and Rai (2026), published in Frontiers in Physiology, brings together ROS-dependent regulation of ferroptosis, autophagy, apoptosis, and immunogenic cell death. Its principal contribution is the integration of processes frequently examined separately into a shared framework of redox-dependent cell-fate control. This perspective raises a timely question: how can oxidative stress be directed toward effective tumor elimination while preserving the physiological functions of surrounding tissues and immune cells?The distinction between tumor-promoting and cytotoxic ROS is often described through a threshold model. Although useful, this model should incorporate more than total ROS abundance. The identity of the reactive species, its site of production, the duration of exposure, and the capacity of antioxidant systems all influence biological outcomes. An increase in mitochondrial oxidants may therefore have different consequences from lipid peroxide accumulation at cellular membranes. Kumari and Rai (2026) emphasize the importance of antioxidant defenses, including NRF2-associated signaling and the SLC7A11-glutathione-GPX4 system. These mechanisms help explain why tumors with elevated oxidative stress can remain viable. For future investigations, the critical issue is whether a tumor depends on a particular protective mechanism and whether disrupting that dependence produces a selective vulnerability. Accordingly, antioxidant protein expression should be interpreted alongside functional measurements of redox adaptation and treatment response.Autophagy illustrates the complexity of redox-dependent cell-fate decisions. By removing damaged organelles and recycling cellular components, it can support survival under oxidative and metabolic stress. Conversely, selective autophagic processes can increase susceptibility to cell death. Hou et al. (2016), for example, demonstrated that autophagy promotes ferroptosis through ferritin degradation, linking intracellular iron mobilization to oxidative injury. These findings argue against treating autophagy activation as evidence of an inevitable lethal response. Increased autophagosome abundance may reflect enhanced formation or impaired degradation, and neither observation alone establishes autophagy-dependent cell death. Future studies should distinguish autophagic flux from static marker accumulation and determine whether autophagy is causally protective or detrimental in the experimental setting. Such distinctions are essential when considering combinations of redox-active agents with autophagy modulators.Another important implication of the review concerns the relationship between oxidative injury and antitumor immunity. Immunogenic cell death describes a functional capacity of dying cells to initiate an adaptive immune response; it should not be assumed to accompany every instance of apoptosis or ferroptosis. Calreticulin exposure, ATP release, and extracellular HMGB1 provide informative measurements, but convincing interpretation requires evidence of immune activation and, where feasible, protective antitumor responses (Galluzzi et al., 2020).The immune consequences of ferroptosis deserve particular attention. Wiernicki et al. (2022) showed that ferroptotic cancer cells can impair dendritic cell-mediated antitumor immunity. This finding qualifies the expectation that lipid peroxidation and damage-associated molecular pattern release will necessarily enhance immune surveillance. The outcome depends on the state of dying cells and the responses of immune populations encountering them. Evaluating tumor cytotoxicity alongside antigen presentation and immune function will therefore be necessary when developing redox-based combination strategies.Progress in this field will depend on connecting molecular mechanisms with tissue-level outcomes. Experiments should establish the source and location of oxidative stress, identify the cell-death mechanism through complementary functional approaches, and assess effects on nonmalignant and immune cells. Patient-derived models can help investigate tumor variability, while immunocompetent systems are particularly important for evaluating claims of immune-mediated efficacy.Treatment timing also warrants investigation. An intervention that initially overwhelms antioxidant defenses may subsequently select for resistant populations or activate protective stress responses. Longitudinal measurements could reveal when redox disruption produces sustained vulnerability and when compensatory adaptation limits its effectiveness.The review by Kumari and Rai (2026) provides a useful foundation for this research agenda. Its broader significance lies in positioning oxidative stress within an interconnected system of cellular maintenance, lethal injury, and immune recognition. The next advance will require defining when, where, and in which cells these responses occur. That understanding could support more precise exploitation of tumor redox vulnerabilities while preserving physiological resilience.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biotechnology, Dr. B. R. Ambedkar University, Srikakulam, Andhra Pradesh, India.
- Laboratory for Cancer Variant Biology, Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, United States.
- Cancer Biology Program, University of Hawaii Cancer Center, Honolulu, HI, United States.
Zitieren
APA
Kumari, S., & Rai, S. K. (2026). Editorial: Reactive oxygen species signaling: opportunities and challenges in cancer therapy. Frontiers in Physiology, 17. https://doi.org/10.3389/fphys.2026.2025961
Vancouver
Kumari S, Rai SK. Editorial: Reactive oxygen species signaling: opportunities and challenges in cancer therapy. Frontiers in Physiology. 2026;17. doi:10.3389/fphys.2026.2025961
BibTeX
@article{Kumari2026,
author = {Kumari, Seema and Rai, Sudhir Kumar},
title = {Editorial: Reactive oxygen species signaling: opportunities and challenges in cancer therapy},
journal = {Frontiers in Physiology},
year = {2026},
volume = {17},
doi = {10.3389/fphys.2026.2025961}
}
EUVIMED